Destiny Pharma (LON:DEST)‘s stock had its “corporate” rating restated by investment analysts at FinnCap in a note issued to investors on Wednesday.

DEST stock opened at GBX 89 ($1.16) on Wednesday. Destiny Pharma has a 1 year low of GBX 111 ($1.45) and a 1 year high of GBX 235 ($3.06).

Destiny Pharma Company Profile

Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.

Read More: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.